Gambogic Acid as a Candidate for Cancer Therapy: A Review

References

• Zhang Y, Li M, Gao X, Chen Y, Liu T. Nanotechnology in cancer diagnosis: progress, challenges and opportunities. J Hematol Oncol. 2019;12(1):137. doi:10.1186/s13045-019-0833-331847897
   PubMed Web of Science ®Google Scholar
• Banik K, Harsha C, Bordoloi D, et al. Therapeutic potential of gambogic acid, a caged xanthone, to target cancer. Cancer Lett. 2018;416:75–86. doi:10.1016/j.canlet.2017.12.01429246645
   PubMed Web of Science ®Google Scholar
• Zhou BD, Weng ZM, Tong YG, et al. Syntheses of xanthone derivatives and their bioactivity investigation. J Asian Nat Prod Res. 2020;1–13.
   PubMed Web of Science ®Google Scholar
• Kashyap D, Mondal R, Tuli HS, Kumar G, Sharma AK. Molecular targets of gambogic acid in cancer: recent trends and advancements. Tumour Biol. 2016;37(10):12915–12925.27448303
   PubMedGoogle Scholar
• Han QB, Cheung S, Tai J, Qiao CF, Song JZ, Xu HX. Stability and cytotoxicity of gambogic acid and its derivative, gambogoic acid. Biol Pharm Bull. 2005;28(12):2335–2337.16327177
   PubMed Web of Science ®Google Scholar
• Wen CY, Huang LL, Chen JX, et al. Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells. Int J Oncol. 2015;47(5):1663–1671.26397804
   PubMed Web of Science ®Google Scholar
• Wang YY, Zhang XJ, Yang YR, Sun HP, You QD. Progress in research of the structural optimization of natural product-like Garcinia caged xanthones. Yao Xue Xue Bao. 2014;49(3):293–302.24961098
   PubMedGoogle Scholar
• Youns M, ElKhoely A, Kamel R. The growth inhibitory effect of gambogic acid on pancreatic cancer cells. N-S Arch Pharmacol. 2018;391(5):551–560.
   PubMed Web of Science ®Google Scholar
• Wang J, Shen W, Yuan ZL, et al. Michael acceptor in gambogic acid-its role and application for potent antitumor agents. Bioorg Med Chem Lett. 2015;25(14):2844–2848.26009165
   PubMed Web of Science ®Google Scholar
• Chen J, Gu H-Y, Lu N, et al. Microtubule depolymerization and phosphorylation of c-Jun N-terminal kinase-1 and p38 were involved in gambogic acid induced cell cycle arrest and apoptosis in human breast carcinoma MCF-7 cells. Life Sci. 2008;83(3–4):103–109. doi:10.1016/j.lfs.2008.05.00318586278
   PubMed Web of Science ®Google Scholar
• Li R, Chen Y, Zeng -L-L, et al. Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt pathway in K562 leukemia cells. Toxicology. 2009;262(2):98–105. doi:10.1016/j.tox.2009.04.05919433130
   PubMed Web of Science ®Google Scholar
• Wang JX, Zhao L, Hu Y, et al. Studies on chemical structure modification and biology of a natural product, Gambogic acid (I): synthesis and biological evaluation of oxidized analogues of gambogic acid. Eur J Med Chem. 2009;44(6):2611–2620. doi:10.1016/j.ejmech.2008.09.03418996626
   PubMed Web of Science ®Google Scholar
• Zhang H-Z, Kasibhatla S, Wang Y, et al. Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg Med Chem. 2004;12(2):309–317. doi:10.1016/j.bmc.2003.11.01314723951
   PubMed Web of Science ®Google Scholar
• Palempalli UD, Gandhi U, Kalantari P, et al. Gambogic acid covalently modifies IκB kinase-β subunit to mediate suppression of lipopolysaccharide-induced activation of NF-κB in macrophages. Biochem J. 2009;419(2):401–409. doi:10.1042/BJ2008148219140805
   PubMedGoogle Scholar
• Yang J, Li C, Ding L, Guo Q, You Q, Jin S. Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain. J Nat Prod. 2012;75(6):1108–1116. doi:10.1021/np300118c22663155
   PubMed Web of Science ®Google Scholar
• Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Curr Drug Targets. 2014;15(1):80–89. doi:10.2174/138945011466614010610141224387333
   PubMed Web of Science ®Google Scholar
• Goldar S, Khaniani MS, Derakhshan SM, Baradaran B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev. 2015;16(6):2129–2144. doi:10.7314/APJCP.2015.16.6.212925824729
   PubMedGoogle Scholar
• Zhai DY, Jin CF, Shiau C-W, Kitada S, Satterthwait AC, Reed JC. Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther. 2008;7(6):1639–1646. doi:10.1158/1535-7163.MCT-07-237318566235
   PubMed Web of Science ®Google Scholar
• Gu HY, Rao SY, Zhao J, et al. Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells. J Cancer Res Clin. 2009;135(12):1777–1782. doi:10.1007/s00432-009-0624-2
   PubMed Web of Science ®Google Scholar
• Gu HY, Wang XT, Rao SY, et al. Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells. Mol Cancer Ther. 2008;7(10):3298–3305. doi:10.1158/1535-7163.MCT-08-021218852133
   PubMed Web of Science ®Google Scholar
• Rong -J-J, Hu R, Qi Q, et al. Gambogic acid down-regulates MDM2 oncogene and induces p21Waf1/CIP1 expression independent of p53. Cancer Lett. 2009;284(1):102–112. doi:10.1016/j.canlet.2009.04.01119428175
   PubMed Web of Science ®Google Scholar
• Wang J, Zhao Q, Qi Q, et al. Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP. J Cell Biochem. 2011;112(2):509–519. doi:10.1002/jcb.2294121268072
   PubMed Web of Science ®Google Scholar
• Davenport J, Manjarrez JR, Peterson L, Krumm B, Blagg BSJ, Matts RL. Gambogic acid, a natural product inhibitor of Hsp90. J Nat Prod. 2011;74(5):1085–1092. doi:10.1021/np200029q21486005
   PubMed Web of Science ®Google Scholar
• Zhang LR, Yi YT, Chen JJ, et al. Gambogic acid inhibits Hsp90 and deregulates TNF-α/NF-κB in HeLa cells. Biochem Bioph Res Co. 2010;403(3–4):282–287. doi:10.1016/j.bbrc.2010.11.018
   PubMed Web of Science ®Google Scholar
• Felth J, Lesiak-Mieczkowska K, D’Arcy P, et al. Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system. Invest New Drug. 2013;31(3):587–598. doi:10.1007/s10637-012-9902-y
   PubMed Web of Science ®Google Scholar
• Li XF, Liu ST, Huang HB, et al. Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo. Cell Rep. 2013;3(1):211–222. doi:10.1016/j.celrep.2012.11.02323260670
   PubMed Web of Science ®Google Scholar
• Shi XP, Lan XY, Chen X, et al. Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition. Sci Rep-Uk. 2015;5.
   Web of Science ®Google Scholar
• Ruiz-Ruiz C, Lopez-Rivas A. Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells. Biochem J. 2002;365(3):825–832.11936954
   PubMedGoogle Scholar
• Smith DJ, Ng H, Kluck RM, Nagley P. The mitochondrial gateway to cell death. IUBMB Life. 2008;60(6):383–389.18425780
   PubMed Web of Science ®Google Scholar
• Guizzunti G, Batova A, Chantarasriwong O, Dakanali M, Theodorakis EA. Subcellular localization and activity of gambogic acid. Chembiochem. 2012;13(8):1191–1198.22532297
   PubMed Web of Science ®Google Scholar
• Li CL, Qi Q, Lu N, et al. Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells. Biochem Cell Biol. 2012;90(6):718–730.23194187
   PubMed Web of Science ®Google Scholar
• Yang J, Li CL, Ding L, Guo QL, You QD, Jin SH. Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain. J Nat Prod. 2012;75(6):1108–1116.22663155
   PubMed Web of Science ®Google Scholar
• Yang LJ, Chen Y, He J, et al. Effects of gambogic acid on the activation of caspase-3 and downregulation of SIRT1 in RPMI-8226 multiple myeloma cells via the accumulation of ROS. Oncol Lett. 2012;3(5):1159–1165.22783411
   PubMed Web of Science ®Google Scholar
• Rahman MA, Kim NH, Huh SO. Cytotoxic effect of gambogic acid on SH-SY5Y neuroblastoma cells is mediated by intrinsic caspase-dependent signaling pathway. Mol Cell Biochem. 2013;377(1–2):187–196.23404459
   PubMed Web of Science ®Google Scholar
• Lee PNH, Ho WS. Antiproliferative activity of gambogic acid isolated from Garcinia hanburyi in Hep3B and Huh7 cancer cells. Oncol Rep. 2013;29(5):1744–1750.23426995
   PubMed Web of Science ®Google Scholar
• Huang GM, Sun Y, Ge X, Wan X, Li CB. Gambogic acid induces apoptosis and inhibits colorectal tumor growth via mitochondrial pathways. World J Gastroentero. 2015;21(20):6194–6205.
   PubMed Web of Science ®Google Scholar
• Thida M, Kim DW, Tran TTT, et al. Gambogic acid induces apoptotic cell death in T98G glioma cells. Bioorg Med Chem Lett. 2016;26(3):1097–1101.26631318
   PubMed Web of Science ®Google Scholar
• Nie FF, Zhang XN, Qi Q, et al. Reactive oxygen species accumulation contributes to gambogic acid-induced apoptosis in human hepatoma SMMC-7721 cells. Toxicology. 2009;260(1–3):60–67.19464570
   PubMed Web of Science ®Google Scholar
• Duan DZ, Zhang BX, Yao J, et al. Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase. Free Radical Bio Med. 2014;69:15–25.24407164
   PubMed Web of Science ®Google Scholar
• Zhu XL, Zhang HM, Lin Y, et al. Mechanisms of gambogic acid-induced apoptosis in non-small cell lung cancer cells in relation to transferrin receptors. J Chemother. 2009;21(6):666–672.20071291
   PubMed Web of Science ®Google Scholar
• Kasibhatla S, Jessen KA, Maliartchouk S, et al. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. P Natl Acad Sci USA. 2005;102(34):12095–12100.
   PubMed Web of Science ®Google Scholar
• Pandey MK, Sung B, Ahn KS, Kunnumakkara AB, Chaturvedi MM, Aggarwal BB. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappa B signaling pathway. Blood. 2007;110(10):3517–3525.17673602
   PubMed Web of Science ®Google Scholar
• Tang QS, Lu MD, Zhou H, Chen DZ, Liu L. Gambogic acid inhibits the growth of ovarian cancer tumors by regulating p65 activity. Oncol Lett. 2017;13(1):384–388.28123571
   PubMed Web of Science ®Google Scholar
• Chen JH, Zhou M, Zhang Q, Xu JY, Ouyang J. Anticancer effect and apoptosis induction of gambogic acid in human leukemia cell line K562 in vitro. Med Sci Mon. 2015;21:1604–1610.
   PubMed Web of Science ®Google Scholar
• Liu WY, Wu X, Liao CQ, Shen J, Li J. Apoptotic effect of gambogic acid in esophageal squamous cell carcinoma cells via suppression of the NF-kappa B pathway. Oncol Lett. 2016;11(6):3681–3685.27284372
   PubMed Web of Science ®Google Scholar
• Prasad S, Pandey MK, Yadav VR, Aggarwal BB. Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis (Retracted article. See vol. 11, pg. 593, 2018). Cancer Prev Res. 2011;4(7):1084–1094.
   PubMed Web of Science ®Google Scholar
• Pan H, Lu LY, Wang XQ, Li BX, Kelly K, Lin HS. Gambogic acid induces cell apoptosis and inhibits MAPK pathway in PTEN-/-/p53(-/-) prostate cancer cells in vitro and ex vivo. Chin J Integr Med. 2018;24(2):109–116.28578487
   PubMed Web of Science ®Google Scholar
• Song HH, Li Y, Ma Y, Ling SK, Ge Z, Huang PL. Induced apoptosis in multiple myeloma cells expressing miR-21 through AKT/FOXO1/BIM signaling. Nanosci Nanotech Let. 2018;10(7):1006–1012.
   Web of Science ®Google Scholar
• Zhu MH, Wang MJ, Jiang YF, et al. Gambogic acid induces apoptosis of non-small cell lung cancer (NSCLC) cells by suppressing notch signaling. Med Sci Mon. 2018;24:7146–7151.
   PubMed Web of Science ®Google Scholar
• Zhang CH, Liu J, Tao FX, et al. The nuclear export of TR3 mediated gambogic acid-induced apoptosis in cervical cancer cells through mitochondrial dysfunction. RSC Adv. 2019;9(21):11855–11864.
   PubMed Web of Science ®Google Scholar
• Li R, Chen Y, Shu WX, Zhao F, Liu Y, Wen L. Effects of gambogic acid on regulation of steroid receptor coactivator-3 in lung adenocarcinoma A549 cells. Chinese J Cancer Res. 2009;21(1):68–73.
   Web of Science ®Google Scholar
• Cui GH, Shu WX, Wu Q, Chen Y. Effect of gambogic acid on the regulation of hERG channel in K562 cells in vitro. J Huazhong U Sci-Med. 2009;29(5):540–545.
   PubMedGoogle Scholar
• Wang YH, Wang W, Sun HQ. Bromodomain-containing protein 4 is critical for the antiproliferative and pro-apoptotic effects of gambogic acid in anaplastic thyroid cancer. Int J Mol Med. 2018;42(1):161–170.29717765
   PubMed Web of Science ®Google Scholar
• He XY, Liu XJ, Chen X, et al. Gambogic acid induces EGFR degradation and Akt/mTORC1 inhibition through AMPK dependent-LRIG1 upregulation in cultured U87 glioma cells. Biochem Bioph Res Co. 2013;435(3):397–402.
   PubMed Web of Science ®Google Scholar
• Gu HG, You QD, Liu W, et al. Gambogic acid induced tumor cell apoptosis by T lymphocyte activation in H-22 transplanted mice. Int Immunopharmacol. 2008;8(11):1493–1502.18573352
   PubMed Web of Science ®Google Scholar
• Zhao W, Zhou SF, Zhang ZP, Xu GP, Li XB, Yan JL. Gambogic acid inhibits the growth of osteosarcoma cells in vitro by inducing apoptosis and cell cycle arrest. Oncol Rep. 2011;25(5):1289–1295.21331449
   PubMed Web of Science ®Google Scholar
• Ye LJ, Zhou JM, Zhao W, Jiao PF, Ren GF, Wang SJ. Gambogic acid-induced autophagy in nonsmall cell lung cancer NCI-H441 cells through a reactive oxygen species pathway. J Cancer Res Ther. 2018;14:S942–S947.30539827
   PubMed Web of Science ®Google Scholar
• Luo GX, Cai J, Lin JZ, et al. Autophagy inhibition promotes gambogic acid-induced suppression of growth and apoptosis in glioblastoma cells. Asian Pac J Cancer P. 2012;13(12):6211–6216.
   PubMedGoogle Scholar
• Zhao T, Wang HJ, Zhao WW, Sun YL, Hu LK. Gambogic acid improves non-small cell lung cancer progression by inhibition of mTOR signaling pathway. Kaohsiung J Med Sci. 2017;33(11):543–549.29050671
   PubMed Web of Science ®Google Scholar
• Foggetti G, Ottaggio L, Russo D, et al. Gambogic acid counteracts mutant p53 stability by inducing autophagy. Bba-Mol Cell Res. 2017;1864(2):382–392.
   PubMed Web of Science ®Google Scholar
• Zhang HY, Lei YL, Yuan P, et al. ROS-mediated autophagy induced by dysregulation of lipid metabolism plays a protective role in colorectal cancer cells treated with gambogic acid. PLoS One. 2014;9(5).
   Web of Science ®Google Scholar
• Ishaq M, Khan MA, Sharma K, Sharma G, Dutta RK, Majumdar S. Gambogic acid induced oxidative stress dependent caspase activation regulates both apoptosis and autophagy by targeting various key molecules (NF-kappa B, Beclin-1, p62 and NBR1) in human bladder cancer cells. Bba-Gen Subjects. 2014;1840(12):3374–3384.
   PubMed Web of Science ®Google Scholar
• Gao GY, Bian YZ, Qian HQ, et al. Gambogic acid regulates the migration and invasion of colorectal cancer via microRNA-21-mediated activation of phosphatase and tensin homolog. Exp Ther Med. 2018;16(3):1758–1765.30186399
   PubMed Web of Science ®Google Scholar
• Zhao K, Zhang S, Song XM, et al. Gambogic acid suppresses cancer invasion and migration by inhibiting TGF beta 1-induced epithelial-to-mesenchymal transition. Oncotarget. 2017;8(16):27120–27136.28404892
   PubMedGoogle Scholar
• Qi Q, Lu N, Li CL, et al. Involvement of RECK in gambogic acid induced anti-invasive effect in A549 human lung carcinoma cells. Mol Carcinogen. 2015;54:E13–E25.
   PubMed Web of Science ®Google Scholar
• Qi Q, Gu HY, Yang Y, et al. Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis. J Mol Med. 2008;86(12):1367–1377.18777017
   PubMed Web of Science ®Google Scholar
• Qi Q, Lu N, Wang XT, et al. Anti-invasive effect of gambogic acid in MDA-MB-231 human breast carcinoma cells. Biochem Cell Biol. 2008;86(5):386–395.18923540
   PubMedGoogle Scholar
• Park MS, Kim NH, Kang CW, Oh CW, Kim GD. Antimetastatic effects of gambogic acid are mediated via the actin cytoskeleton and NF-B pathways in SK-HEP1 cells. Drug Develop Res. 2015;76(3):132–142.
   PubMed Web of Science ®Google Scholar
• Lu L, Tang D, Wang L, et al. Gambogic acid inhibits TNF-alpha-induced invasion of human prostate cancer PC3 cells in vitro through PI3K/Akt and NF-kappa B signaling pathways. Acta Pharmacol Sin. 2012;33(4):531–541.22426696
   PubMed Web of Science ®Google Scholar
• Xin ZF, Shen CC, Tao LJ, Yan SG, Wu HB. Gambogic acid inhibits invasion of osteosarcoma via upregulation of TIMP-1. Int J Mol Med. 2013;31(1):105–112.23175213
   PubMed Web of Science ®Google Scholar
• Zhao J, Qi Q, Yang Y, et al. Inhibition of alpha(4) integrin mediated adhesion was involved in the reduction of B16-F10 melanoma cells lung colonization in C57BL/6 mice treated with Gambogic acid. Eur J Pharmacol. 2008;589(1–3):127–131.18539272
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang Z, Peng Q, et al. Tumor refractoriness to endostatin anti-angiogenesis is associated with the recruitment of CD11b+Gr1+ myeloid cells and inflammatory cytokines. Tumori. 2013;99(6):723–733.24503797
   PubMed Web of Science ®Google Scholar
• Wang F, Zhang W, Guo LT, et al. Gambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target protein of rapamycin pathway in multiple myeloma cells. Cancer Sci. 2014;105(8):1063–1070.24890366
   PubMed Web of Science ®Google Scholar
• Lu N, Hui H, Yang H, et al. Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1 alpha pathway. Eur J Pharm Sci. 2013;49(2):220–226.23501055
   PubMed Web of Science ®Google Scholar
• Yi T, Yi Z, Cho SG, et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res. 2008;68(6):1843–1850.18339865
   PubMed Web of Science ®Google Scholar
• Assaraf YG, Brozovic A, Goncalves AC, et al. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Updat. 2019;46:100645.31585396
   PubMed Web of Science ®Google Scholar
• Wang Q, Wei JC, Wang CX, et al. Gambogic acid reverses oxaliplatin resistance in colorectal cancer by increasing intracellular platinum levels. Oncol Lett. 2018;16(2):2366–2372.30008940
   PubMed Web of Science ®Google Scholar
• Xia GG, Wang HC, Song ZL, Meng QC, Huang XY, Huang XY. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). J Exp Clin Canc Res. 2017;36.
   Web of Science ®Google Scholar
• Zhao W, Xia SQ, Zhuang JP, et al. Hypoxia-induced resistance to cisplatin-mediated apoptosis in osteosarcoma cells is reversed by gambogic acid independently of HIF-1 alpha. Mol Cell Biochem. 2016;420(1–2):1–8.27473145
   PubMed Web of Science ®Google Scholar
• Wang SP, Wang L, Chen MW, Wang YT. Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression. Chem-Biol Interact. 2015;235:76–84.25824409
   PubMed Web of Science ®Google Scholar
• Wang TT, Wei J, Qlan XP, Ding YT, Yu LX, Liu BR. Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett. 2008;262(2):214–222.18248784
   PubMed Web of Science ®Google Scholar
• Wang CD, Wang W, Wang CY, Tang YJ, Tian H. Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer. Oncol Lett. 2015;10(4):2063–2066.26622796
   PubMed Web of Science ®Google Scholar
• Xia Y, Zhong J, Zhao M, et al. Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma. Drug Deliv. 2019;26(1):1–11.31928356
   PubMed Web of Science ®Google Scholar
• Xia Y, Tang G, Wang C, et al. Functionalized selenium nanoparticles for targeted siRNA delivery silence Derlin1 and promote antitumor efficacy against cervical cancer. Drug Deliv. 2020;27(1):15–25.31830840
   PubMed Web of Science ®Google Scholar
• Xia Y, Tang G, Guo M, et al. Silencing KLK12 expression via RGDfC-decorated selenium nanoparticles for the treatment of colorectal cancer in vitro and in vivo. Mater Sci Eng C Mater Biol Appl. 2020;110:110594.32204058
   PubMed Web of Science ®Google Scholar
• Yu G, Ning Q, Mo Z, Tang S. Intelligent polymeric micelles for multidrug co-delivery and cancer therapy. Artif Cells Nanomed Biotechnol. 2019;47(1):1476–1487.31070063
   PubMed Web of Science ®Google Scholar
• Hwang D, Ramsey JD, Kabanov AV. Polymeric micelles for the delivery of poorly soluble drugs: from nanoformulation to clinical approval. Adv Drug Deliv Rev. 2020.
   PubMed Web of Science ®Google Scholar
• Attia ABE, Ong ZY, Hedrick JL, et al. Mixed micelles self-assembled from block copolymers for drug delivery. Curr Opin Colloid Interface Sci. 2011;16(3):182–194.
   Web of Science ®Google Scholar
• Saxena V, Hussain MD. Poloxamer 407/TPGS mixed micelles for delivery of gambogic acid to breast and multidrug-resistant cancer. Int J Nanomed. 2012;7:713–721.
   PubMed Web of Science ®Google Scholar
• Yu F, Jiang FG, Tang XH, Wang BC. N-octyl-N-arginine-chitosan micelles for gambogic acid intravenous delivery: characterization, cell uptake, pharmacokinetics, and biodistribution. Drug Dev Ind Pharm. 2018;44(4):615–623.29188736
   PubMed Web of Science ®Google Scholar
• Wang SP, Yang Y, Wang YT, Chen MW. Gambogic acid-loaded pH-sensitive mixed micelles for overcoming breast cancer resistance. Int J Pharmaceut. 2015;495(2):840–848.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liang XFQ, Tong RS, et al. Gambogic acid-loaded polymeric micelles for improved therapeutic effect in breast cancer. J Biomed Nanotechnol. 2018;14(10):1695–1704.30041717
   PubMed Web of Science ®Google Scholar
• Yu F, He CH, Waddad AY, et al. N-octyl-N-arginine-chitosan (OACS) micelles for gambogic acid oral delivery: preparation, characterization and its study on in situ intestinal perfusion. Drug Dev Ind Pharm. 2014;40(6):774–782.23679668
   PubMed Web of Science ®Google Scholar
• Sang MM, Liu FL, Wang Y, et al. A novel redox/pH dual-responsive and hyaluronic acid-decorated multifunctional magnetic complex micelle for targeted gambogic acid delivery for the treatment of triple negative breast cancer. Drug Deliv. 2018;25(1):1846–1857.30334478
   PubMed Web of Science ®Google Scholar
• Ke ZC, Yang L, Wu H, Li ZH, Jia XB, Zhang ZH. Evaluation of in vitro and in vivo antitumor effects of gambogic acid-loaded layer-by-layer self-assembled micelles. Int J Pharmaceut. 2018;545(1–2):306–317.
   PubMed Web of Science ®Google Scholar
• Yan XF, Yang Y, He LQ, Peng DY, Yin DK. Gambogic acid grafted low molecular weight heparin micelles for targeted treatment in a hepatocellular carcinoma model with an enhanced anti-angiogenesis effect. Int J Pharmaceut. 2017;522(1–2):110–118.
   PubMed Web of Science ®Google Scholar
• Xu YQ, Wang SP, Chan HF, et al. Triphenylphosphonium-modified poly(ethylene glycol)-poly(epsilon-caprolactone) micelles for mitochondria- targeted gambogic acid delivery. Int J Pharmaceut. 2017;522(1–2):21–33.
   PubMed Web of Science ®Google Scholar
• Luo S, Tan X, Fang S, et al. MItochondria-targeted small-molecule fluorophores for dual modal cancer phototherapy. Adv Funct Mater. 2016;26(17):2826–2835.
   Web of Science ®Google Scholar
• Liang H, Zhou ZW, Luo RJ, et al. Tumor-specific activated photodynamic therapy with an oxidation-regulated strategy for enhancing anti-tumor efficacy. Theranostics. 2018;8(18):5059–5071.30429886
   PubMed Web of Science ®Google Scholar
• Vangijzegem T, Stanicki D, Laurent S. Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics. Expert Opin Drug Deliv. 2019;16(1):69–78. doi:10.1080/17425247.2019.155464730496697
   PubMed Web of Science ®Google Scholar
• Wang CL, Zhang HJ, Chen BA, Yin HT, Wang WW. Study of the enhanced anticancer efficacy of gambogic acid on Capan-1 pancreatic cancer cells when mediated via magnetic Fe3O4 nanoparticles. Int J Nanomed. 2011;6:1929–1935.
   PubMed Web of Science ®Google Scholar
• Wang CL, Zhang HJ, Chen Y, Shi FF, Chen BA. Gambogic acid-loaded magnetic Fe3O4 nanoparticles inhibit Panc-1 pancreatic cancer cell proliferation and migration by inactivating transcription factor ETS1. Int J Nanomed. 2012;7:781–787.
   PubMed Web of Science ®Google Scholar
• Chen BA, Liang Y, Wu W, et al. Synergistic effect of magnetic nanoparticles of Fe3O4 with gambogic acid on apoptosis of K562 leukemia cells. Int J Nanomed. 2009;4:251–259. doi:10.2147/IJN.S7932
   PubMed Web of Science ®Google Scholar
• Fang LH, Chen BA, Liu SL, et al. Synergistic effect of a combination of nanoparticulate Fe3O4 and gambogic acid on phosphatidylinositol 3-kinase/Akt/Bad pathway of LOVO cells. Int J Nanomed. 2012;7:4109–4118.
   PubMed Web of Science ®Google Scholar
• Wang WW, Li XY, Wang ZH, et al. A novel “mosaic-type” nanoparticle for selective drug release targeting hypoxic cancer cells. Nanoscale. 2019;11(5):2211–2222. doi:10.1039/C8NR06452K30656317
   PubMed Web of Science ®Google Scholar
• Zhang Z, Qian HQ, Huang J, et al. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment. Int J Nanomed. 2018;13:4961–4975. doi:10.2147/IJN.S170148
   PubMed Web of Science ®Google Scholar
• Zhang DH, Zou ZY, Ren W, et al. Gambogic acid-loaded PEG–PCL nanoparticles act as an effective antitumor agent against gastric cancer. Pharm Dev Technol. 2018;23(1):33–40. doi:10.1080/10837450.2017.129506829069711
   PubMed Web of Science ®Google Scholar
• Zhang Z, Qian HQ, Yang M, et al. Gambogic acid-loaded biomimetic nanoparticles in colorectal cancer treatment. Int J Nanomed. 2017;12:1593–1605. doi:10.2147/IJN.S127256
   PubMed Web of Science ®Google Scholar
• Wang SP, Shao M, Zhong ZF, et al. Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer. Drug Deliv. 2017;24(1):1791–1800. doi:10.1080/10717544.2017.140655829172759
   PubMed Web of Science ®Google Scholar
• He MY, Ro LL, Liu J, Chu -C-C. Folate-decorated arginine-based poly(ester urea urethane) nanoparticles as carriers for gambogic acid and effect on cancer cells. J Biomed Mater Res A. 2017;105(2):475–490. doi:10.1002/jbm.a.3592427706899
   PubMed Web of Science ®Google Scholar
• Li R, He Y, Zhang S, Qin J, Wang J. Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment. Acta Pharm Sin B. 2018;8(1):14–22. doi:10.1016/j.apsb.2017.11.00929872619
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang ZJ, Tan XY, Tang X, Yang ZX. Development of a more efficient albumin-based delivery system for gambogic acid with low toxicity for lung cancer therapy. Aaps Pharmscitech. 2017;18(6):1987–1997. doi:10.1208/s12249-016-0670-427933587
   PubMed Web of Science ®Google Scholar
• Fang XB, Xu YQ, Wang SP, Wan JB, He CW, Chen MW. Pluronic F68-linoleic acid nano-spheres mediated delivery of gambogic acid for cancer therapy. Aaps Pharmscitech. 2017;18(1):147–155.26912357
   PubMed Web of Science ®Google Scholar
• Yang K, Xu H, Cheng L, Sun C, Wang J, Liu Z. In vitro and in vivo near-infrared photothermal therapy of cancer using polypyrrole organic nanoparticles. Adv Mater. 2012;24(41):5586–5592. doi:10.1002/adma.20120262522907876
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhu WJ, Dong ZL, et al. 1D coordination polymer nanofibers for low-temperature photothermal therapy. Adv Mater. 2017;29:40.
   Web of Science ®Google Scholar
• Haine AT, Niidome T. Gold nanorods as nanodevices for bioimaging, photothermal therapeutics, and drug delivery. Chem Pharm Bull (Tokyo). 2017;65(7):625–628. doi:10.1248/cpb.c17-0010228674334
   PubMed Web of Science ®Google Scholar
• Wan H-Y, Chen J-L, Yu X-Y, Zhu X-M. Titania-coated gold nanorods as an effective carrier for gambogic acid. RSC Adv. 2017;7(78):49518–49525. doi:10.1039/C7RA08560E
   Web of Science ®Google Scholar
• Ji Y, Shan S, He MY, Chu -C-C. Inclusion complex from cyclodextrin-grafted hyaluronic acid and pseudo protein as biodegradable nano-delivery vehicle for gambogic acid. Acta Biomater. 2017;62:234–245. doi:10.1016/j.actbio.2017.08.03628859900
   PubMed Web of Science ®Google Scholar
• Zhan Q, Tang M. Research advances on apoptosis caused by quantum dots. Biol Trace Elem Res. 2014;161(1):3–12. doi:10.1007/s12011-014-0068-725062887
   PubMed Web of Science ®Google Scholar
• Xu PP, Li JY, Shi LX, Selke M, Chen BA, Wang XM. Synergetic effect of functional cadmium–tellurium quantum dots conjugated with gambogic acid for HepG2 cell-labeling and proliferation inhibition. Int J Nanomed. 2013;8:3729–3736. doi:10.2147/IJN.S51622
   PubMed Web of Science ®Google Scholar
• Kang YA, Lu L, Lan JS, et al. Redox-responsive polymeric micelles formed by conjugating gambogic acid with bioreducible poly(amido amine)s for the co-delivery of docetaxel and MMP-9 shRNA. Acta Biomater. 2018;68:137–153. doi:10.1016/j.actbio.2017.12.02829288085
   PubMed Web of Science ®Google Scholar
• Huang WZ, Wang X, Shi CY, et al. Fine-tuning vitamin E-containing telodendrimers for efficient delivery of gambogic acid in colon cancer treatment. Mol Pharmaceut. 2015;12(4):1216–1229. doi:10.1021/acs.molpharmaceut.5b00051
   PubMed Web of Science ®Google Scholar
• Zhang Y, Tan XY, Ren TY, Jia C, Yang ZX, Sun H. Folate-modified carboxymethyl-chitosan/polyethylenimine/bovine serum albumin based complexes for tumor site-specific drug delivery. Carbohyd Polym. 2018;198:76–85. doi:10.1016/j.carbpol.2018.06.055
   PubMed Web of Science ®Google Scholar
• Yang Y, Cai HX, Yuan XY, et al. Efficient targeting drug delivery system for lewis lung carcinoma, leading to histomorphological abnormalities restoration, physiological and psychological statuses improvement, and metastasis inhibition. Mol Pharmaceut. 2018;15(5):2007–2016.
   PubMed Web of Science ®Google Scholar
• Tian FC, Dahmani FZ, Qiao JN, et al. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer. Acta Biomater. 2018;75:398–412. doi:10.1016/j.actbio.2018.05.05029874597
   PubMed Web of Science ®Google Scholar
• Xu YW, Wang CY, Ding YF, et al. Nanoparticles with optimal ratiometric co-delivery of docetaxel with gambogic acid for treatment of multidrug-resistant breast cancer. J Biomed Nanotechnol. 2016;12(9):1774–1781. doi:10.1166/jbn.2016.228229345888
   PubMed Web of Science ®Google Scholar
• Liu L, Qi X-J, Zhong Z-K, Zhang E-N. Nanomedicine-based combination of gambogic acid and retinoic acid chlorochalcone for enhanced anticancer efficacy in osteosarcoma. Biomed Pharmacother. 2016;83:79–84. doi:10.1016/j.biopha.2016.06.00127470553
   PubMed Web of Science ®Google Scholar
• Dahmani FZ, Xiao Y, Zhang J, Yu Y, Zhou JP, Yao J. Multifunctional polymeric nanosystems for dual-targeted combinatorial chemo/antiangiogenesis therapy of tumors. Adv Healthc Mater. 2016;5(12):1447–1461. doi:10.1002/adhm.20160016927125765
   PubMed Web of Science ®Google Scholar
• Yao J, Li YK, Sun XJ, Dahmani FZ, Liu HP, Zhou JP. Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid. Int J Nanomed. 2014;9:3313–3324. doi:10.2147/IJN.S62793
   PubMed Web of Science ®Google Scholar
• Doddapaneni R, Patel K, Owaid IH, Singh M. Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer. Drug Deliv. 2016;23(4):1232–1241. doi:10.3109/10717544.2015.112447226701717
   PubMed Web of Science ®Google Scholar
• Zhao W, You -C-C, Zhuang J-P, et al. Viability inhibition effect of gambogic acid combined with cisplatin on osteosarcoma cells via mitochondria-independent apoptotic pathway. Mol Cell Biochem. 2013;382(1–2):243–252. doi:10.1007/s11010-013-1740-523812885
   PubMed Web of Science ®Google Scholar
• Zou ZY, Xie L, Wei J, et al. Synergistic anti-proliferative effects of gambogic acid with docetaxel in gastrointestinal cancer cell lines. BMC Complement Altern Med. 2012;12(1):1–9. doi:10.1186/1472-6882-12-58
   Google Scholar
• Wang J, Liu W, Zhao Q, et al. Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology. 2009;256(1–2):135–140. doi:10.1016/j.tox.2008.11.01419084572
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang RJ, Chen B, Sun D, Hu Y, Xu PP. Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo. Int J Nanomed. 2016;11:5429–5442. doi:10.2147/IJN.S115037
   PubMed Web of Science ®Google Scholar